Ted D. Kellner v. AIM ImmunoTech Inc.

CourtSupreme Court of Delaware
DecidedJuly 11, 2024
Docket3, 2024
StatusPublished

This text of Ted D. Kellner v. AIM ImmunoTech Inc. (Ted D. Kellner v. AIM ImmunoTech Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ted D. Kellner v. AIM ImmunoTech Inc., (Del. 2024).

Opinion

EFiled: Jul 11 2024 03:04PM EDT Filing ID 73633189 Case Number 3,2024 IN THE SUPREME COURT OF THE STATE OF DELAWARE

TED D. KELLNER, § § No. 3, 2024 Plaintiff Below, § Appellant/Cross-Appellee, § Court Below: Court of Chancery § of the State of Delaware v. § § C.A. No. 2023-0879 AIM IMMUNOTECH INC., § THOMAS EQUELS, WILLIAM § MITCHELL, STEWART § APPELROUTH, and NANCY K. § BRYAN, § § Defendants Below, § Appellees/Cross- § Appellants. §

Submitted: April 10, 2024 Decided: July 11, 2024

Before SEITZ, Chief Justice; VALIHURA, TRAYNOR, LEGROW, and GRIFFITHS, Justices; constituting the Court en Banc.

Upon appeal from the Court of Chancery. AFFIRMED in part, REVERSED in part.

John M. Seaman, Esquire, Eliezer Y. Feinstein, Esquire, ABRAMS & BAYLISS LLP, Wilmington, Delaware; Teresa Goody Guillén, Esquire, Richard Raile, Esquire (argued), BAKER & HOSTETLER LLP, Washington, D.C.; Marco Molina, Esquire, BAKER & HOSTETLER LLP, Costa Mesa, California; Alexandra L. Trujillo, Esquire, BAKER & HOSTETLER LLP, Houston, Texas for Plaintiff Below, Appellant/Cross-Appellee Ted D. Kellner.

William R. Denny, Esquire, Matthew F. Davis, Esquire, Nicholas D. Mozal, Esquire, Caneel Radinson-Blasucci, Esquire, Eric J. Nascone, Esquire, POTTER ANDERSON & CORROON LLP, Wilmington, Delaware; Stefan Atkinson, Esquire (argued), Mary T. Reale, Esquire, Mason E. Reynolds, Esquire, Joseph Taglienti, Esquire, KIRKLAND & ELLIS LLP, New York, New York; Michael F. Williams, Esquire, Don Hong, Esquire, KIRKLAND & ELLIS LLP, Washington D.C. for Defendants Below, Appellees/Cross-Appellants AIM ImmunoTech Inc., Thomas Equels, William Mitchell, Stewart Appelrouth, and Nancy K. Bryan.

Brett M. McCartney, Esquire, Sarah T. Andrade, Esquire, BAYARD, P.A., Wilmington, Delaware; Edward J. Fuhr, Esquire, Steven M. Haas, Esquire, Johnathon E. Schronce, Esquire, James M. Lockerby, Esquire, HUNTON ANDREWS KURTH LLP, Richmond, Virginia for Amicus Curiae, Chamber of Commerce of the United States of America, in support of Appellees.

2 SEITZ, Chief Justice:

A group of AIM ImmunoTech, Inc. stockholders thought that the board of

directors was mismanaging the company. They launched an activism campaign and

proxy contest to elect new directors. The insurgents included two felons convicted

of wire fraud, insider trading, and other crimes. The campaign escalated into two

attempts to nominate directors to the AIM board.

The board rejected both nomination notices under its existing bylaws, which

led to a lawsuit over the second notice. The Court of Chancery denied the

insurgents’ request for a mandatory preliminary injunction to place their nominees

on the annual meeting ballot. The court held that factual disputes about the veracity

of the insurgents’ disclosures precluded temporary mandatory injunctive relief.

Undeterred, the insurgents reshuffled their membership, with Ted D. Kellner

leading a third attempt to nominate three new directors to the AIM board.

Meanwhile, the board amended its bylaws to include sweeping new advance notice

provisions. The amended bylaws required detailed disclosures by Kellner and his

nominees. Many of the amendments were approved by the AIM board as a direct

response to the insurgents’ campaign.

The AIM board once again rejected Kellner’s nominations for failing to

comply with the new advance notice bylaws. Kellner filed suit. After trial, the Court

of Chancery invalidated four of the six main advance notice bylaws and reinstated

3 the 2016 version of one of the invalidated bylaws. Ultimately, the court upheld the

board’s rejection of the third nomination notice because it failed to comply with the

two advance notice bylaws left standing, including the reinstated 2016 bylaw

provision.

On appeal, Kellner argues that the court improperly used the 2016 bylaw to

reject his notice because the AIM board did not rely on it as a basis for rejection. In

addition, according to Kellner, the enactment of the amended bylaws repealed the

2016 bylaw, which meant that the court had no basis to reinstate it. He also argues

that the court erred when it held that two of the amended bylaws withstood enhanced

scrutiny when, at the same time, the court found that many of the other bylaws were

preclusive and adopted for an improper purpose. Finally, Kellner contends that the

court erred when it found that the nomination notice did not comply with the

amended bylaws left standing.

By way of cross appeal, the defendants object to the Court of Chancery’s

invalidation of four of the amended bylaws. As they argue, the Court of Chancery

erred when it confused a “facial” challenge to the bylaws with an “as-applied”

challenge. According to the defendants, Kellner brought only an as-applied

challenge. The court, therefore, should not have invalidated the amended bylaws.

The defendants also contend that, in any event, the amended bylaws withstand

enhanced scrutiny review.

4 In a challenge to the adoption, amendment, or enforcement of a Delaware

corporation’s advance notice bylaws that is ripe for judicial review, the court should

consider the following: first, if contested, whether the advance notice bylaws are

valid as consistent with the certificate of incorporation, not prohibited by law, and

address a proper subject matter; and second, whether the board’s adoption,

amendment, or application of the advance notice bylaws were equitable under the

circumstances of the case.

Applying this framework to the current appeal, we hold that: (1) one

“unintelligible” bylaw is invalid; (2) the remaining amended advance notice bylaws

subject to this appeal are valid because they are consistent with the certificate of

incorporation, not prohibited by law, and address a proper subject matter; and (3)

the AIM board acted inequitably when it adopted the amended bylaws for the

primary purpose of interfering with, and ultimately rejecting, Kellner’s nominations.

Thus, the remaining bylaws challenged on appeal are unenforceable.

I.

A.

We rely on the facts as found after trial.1 AIM ImmunoTech, Inc. is a publicly

traded pharmaceutical company incorporated in Delaware and headquartered in

1 Kellner v. AIM ImmunoTech Inc., 307 A.3d 998 (Del. Ch. 2023).

5 Florida. AIM develops treatments for immune system disorders, viral diseases, and

cancers. Its lead product is the investigational drug Ampligen. AIM has a four-

member board of directors – Thomas Equels, William Mitchel, Stewart Appelrouth,

and Nancy K. Bryan. Equels is AIM’s Chief Executive Officer, having served in his

role since 2008. Mitchell, a scientist who has studied Ampligen since the 1980s, is

the chairman of the board. Appelrouth, an accountant, has served on the board since

2016. Bryan, the President of BioFlorida Inc., an LLC of which AIM is a member,

is the latest addition, beginning her board tenure in March, 2023. The directors and

the company are the defendants in the litigation.

Ted D. Kellner, the plaintiff in this litigation, is a retired founder, portfolio

manager, philanthropist, minority owner of a professional basketball team, and a

major AIM stockholder. In 2023, Kellner sought to nominate a competing slate of

directors to serve on the AIM board. The competing slate of directors was Kellner

himself, Todd Deutsch, and Robert Chioini. Deutsch, a private investor, has known

Kellner for over two decades and is the owner of about 3.5% of AIM’s shares.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mentor Graphics Corp. v. Quickturn Design Systems, Inc.
728 A.2d 25 (Court of Chancery of Delaware, 1998)
Blasius Industries, Inc. v. Atlas Corp.
564 A.2d 651 (Court of Chancery of Delaware, 1988)
Quickturn Design Systems, Inc. v. Shapiro
721 A.2d 1281 (Supreme Court of Delaware, 1998)
QVC Network, Inc. v. Paramount Communications Inc.
635 A.2d 1245 (Court of Chancery of Delaware, 1993)
Black v. Hollinger International Inc.
872 A.2d 559 (Supreme Court of Delaware, 2005)
Gotham Partners, L.P. v. Hallwood Realty Partners, L.P.
817 A.2d 160 (Supreme Court of Delaware, 2002)
Michelson v. Duncan
407 A.2d 211 (Supreme Court of Delaware, 1979)
Openwave Systems Inc. v. Harbinger Capital Partners Master Fund I, Ltd.
924 A.2d 228 (Court of Chancery of Delaware, 2007)
Unitrin, Inc. v. American General Corp.
651 A.2d 1361 (Supreme Court of Delaware, 1995)
Levitt v. Bouvier
287 A.2d 671 (Supreme Court of Delaware, 1972)
Weinberger v. UOP, Inc.
457 A.2d 701 (Supreme Court of Delaware, 1983)
Hollinger International, Inc. v. Black
844 A.2d 1022 (Court of Chancery of Delaware, 2004)
Frantz Manufacturing Co. v. EAC Industries
501 A.2d 401 (Supreme Court of Delaware, 1985)
Stroud v. Milliken Entersprises, Inc.
552 A.2d 476 (Supreme Court of Delaware, 1989)
Unocal Corp. v. Mesa Petroleum Co.
493 A.2d 946 (Supreme Court of Delaware, 1985)
Rollins International, Inc. v. International Hydronics Corp.
303 A.2d 660 (Supreme Court of Delaware, 1973)
Chesapeake Corp. v. Shore
771 A.2d 293 (Court of Chancery of Delaware, 2000)
CA, Inc. v. AFSCME Employees Pension Plan
953 A.2d 227 (Supreme Court of Delaware, 2008)
Lerman v. Diagnostic Data, Inc.
421 A.2d 906 (Court of Chancery of Delaware, 1980)
MM Companies, Inc. v. Liquid Audio, Inc.
813 A.2d 1118 (Supreme Court of Delaware, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
Ted D. Kellner v. AIM ImmunoTech Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/ted-d-kellner-v-aim-immunotech-inc-del-2024.